Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
Rhythm Pharmaceuticals announced the publication of a new, evidence-based diagnostic algorithm for Bardet-Biedl syndrome (BBS) in the American Journal of Medical Genetics. The algorithm, co-authored by Rhythm-funded experts including Professor Philip Beales, aims to streamline diagnosis and reduce the time to informed care for BBS patients. This supports the addressable market for Rhythm’s approved drug IMCIVREE (setmelanotide), which is indicated for obesity associated with BBS.
Key figures
- Bbs genes
- 28
- Bbs us patients
- 4,000-5,000
- Bbs europe patients
- 4,000-5,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.